Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SP0202 PCV Candidate in Healthy Adults
NCT06698198Phase 1Completed
- Sponsor
- Sanofi
- Start
- Dec 2018
- Primary completion
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of SP0202 in pneumococcal infection (5 arms), sponsored by Sanofi. Primary endpoints: Occurrence of unsolicited systemic AEs reported in the 30 minutes after injection at 30 months, Occurrence of solicited injection site and systemic reactions at 7 days and 3 more. Started Dec 2018; status: completed.
02
Drugs
SP0202
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT06698198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698198.